Skip to content

Study · Non-randomized trial · n = 7 · 2007

4 results

IRX-2 and thymosin alpha1 (Zadaxin) increase T lymphocytes in T lymphocytopenic mice and humans.

Hadden JW, Verastegui E, Hadden E

Annals of the New York Academy of Sciences28 Jun 2007Cited by 11 (Europe PMC)

PMID17600288 (opens in a new tab)DOI10.1196/annals.1415.032 (opens in a new tab)PepBankPUB-17600288
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In lymphocytopenic cancer patients, adding Talpha1 to IRX-2 markedly increased lymphocyte populations, whereas IRX-2 alone had little or no significant effect.

    In plain wordsIn patients with low lymphocyte counts, adding Talpha1 to IRX-2 raised immune cell counts, while IRX-2 alone did little.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseLymphocyte counts: IRX-2 plus Talpha1 versus IRX-2 alone
    Study

    n = 7

    Comparator
    IRX-2 alone
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    1.6 mg/day · subcutaneous · 10 daysAs given in this study (human).

    Measurements

    Increase in lymphocyte populations with combination
    > 350 cells/microL
    IRX-2 plus Talpha1

    Source sentences

    Summary
    IRX-2 and Talpha1 had little or no significant effect. The combination markedly increased various lymphocyte populations (>350 cells/microL).
    2 context sentences
    Summary · context
    Patients (seven) were treated with subcutaneously injected IRX-2 (200 units IL-2 equivalence), Talpha1 (1.6 mg/day) (four patients), or the combination of IRX-2 and Talpha1 (seven patients) daily for 10 days.
    Summary · context
    Peripheral blood lymphocytes (T, B, NK) and subsets (CD4, CD8) were measured at the start of treatment and on day 11.
  2. 02HumanNon-randomized trialEfficacy outcome

    In lymphocytopenic cancer patients, Talpha1 alone had little or no significant effect on lymphocyte populations.

    In plain wordsIn patients with low lymphocyte counts, Talpha1 alone had little or no clear effect on immune cell counts.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeLymphocyte counts with Talpha1 alone
    Study

    n = 4

    Comparator
    Baseline
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    1.6 mg/day · subcutaneous · 10 daysAs given in this study (human).

    Source sentences

    Summary
    IRX-2 and Talpha1 had little or no significant effect.
    2 context sentences
    Summary · context
    Patients (seven) were treated with subcutaneously injected IRX-2 (200 units IL-2 equivalence), Talpha1 (1.6 mg/day) (four patients), or the combination of IRX-2 and Talpha1 (seven patients) daily for 10 days.
    Summary · context
    Peripheral blood lymphocytes (T, B, NK) and subsets (CD4, CD8) were measured at the start of treatment and on day 11.

Studies that did not test the peptide alone2

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 03HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome

    In four lymphocytopenic patients treated with IRX-2 plus Talpha1 and followed for 6 weeks, increases in naive and memory T cells were sustained.

    In plain wordsIn four patients given IRX-2 plus Talpha1, increases in T cells lasted for 6 weeks.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseSustained T cell increases at 6 weeks with IRX-2 plus Talpha1
    Study

    n = 4

    Comparator
    Baseline
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Four patients followed for 6 weeks displayed sustained increases involving both naïve and memory T cells.
    2 context sentences
    Summary · context
    Patients (seven) were treated with subcutaneously injected IRX-2 (200 units IL-2 equivalence), Talpha1 (1.6 mg/day) (four patients), or the combination of IRX-2 and Talpha1 (seven patients) daily for 10 days.
    Summary · context
    Peripheral blood lymphocytes (T, B, NK) and subsets (CD4, CD8) were measured at the start of treatment and on day 11.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 04HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialSafety outcome

    In four patients treated with IRX-2 plus Talpha1, responses to persistent infections occurred in three and no significant toxicity was observed.

    In plain wordsIn four patients given IRX-2 plus Talpha1, three responded to persistent infections and no significant toxicity was seen.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeToxicity and response to persistent infections with IRX-2 plus Talpha1
    Study

    n = 4

    Outcome group
    Adverse events · Immune and inflammation

    Source sentences

    Summary
    Responses to persistent infections were observed in three of the four patients and no significant toxicity was observed.
    2 context sentences
    Summary · context
    Patients (seven) were treated with subcutaneously injected IRX-2 (200 units IL-2 equivalence), Talpha1 (1.6 mg/day) (four patients), or the combination of IRX-2 and Talpha1 (seven patients) daily for 10 days.
    Summary · context
    Peripheral blood lymphocytes (T, B, NK) and subsets (CD4, CD8) were measured at the start of treatment and on day 11.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.